Sanofi Gets Full Commercial Control on Virus Medication From AstraZeneca in U.S.
11 Abril 2023 - 03:54AM
Dow Jones News
By Cecilia Butini
Sanofi SA and AstraZeneca PLC said Monday that Sanofi would
retain full commercial control on an antibody treatment for
respiratory syncytial virus in the U.S. as part of a contractual
agreement between the two companies and Swedish Orphan Biovitrum
AB.
Under the new arrangements, Swedish Orphan Biovitrum, known as
Sobi, will terminate its participation agreement with AstraZeneca
and will enter into a direct royalty agreement with Sanofi to share
a portion of U.S. net sales of the drug.
The drug, named nirsevimab, will still be jointly commercialized
by Sanofi and AstraZeneca in territories outside the U.S., said
Sanofi.
Sobi had said on April 9 that it would pay Sanofi $66 million as
reimbursement for prior research-and-development costs for the
treatment in the U.S., and that it would receive quarterly
royalties on net U.S. sales of the drug from Sanofi. Royalty rates
will start at 25% at launch in 2023, will continue in 2024 and will
increase each year until 2028, reaching a range of 30% to 35% of
net sales, said Sobi.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 11, 2023 02:39 ET (06:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024